inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemija, mieloid - antineoplastična sredstva - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
dacogen
janssen-cilag international n.v. - decitabin - leukemija, mieloid - antineoplastična sredstva - liječenje odraslih bolesnika s novodijagnosticiranom de novo ili sekundarne akutne mijeloične leukemije (aml), prema klasifikaciji svjetske zdravstvene organizacije (who), koji nisu kandidati za standardni kemoterapije.
gemcitabine venus 200 mg/1 bočica prašak za rastvor za infuziju
corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 200 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)
gemcitabine venus 1000 mg/1 bočica prašak za rastvor za infuziju
corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 1000 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 1000 mg gemcitabina (u obliku gemcitabinhidrohlorida)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
pemetreksed lek 500 mg/1 bočica prašak za rastvor za infuziju
novartis ba d.o.o. - pemetreksed - prašak za rastvor za infuziju - 500 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži: 500 mg pemetrekseda (u obliku pemetreksed dinatrija)
imfinzi
astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
gemcitabin ebewe 10 mg/1 ml koncentrat za rastvor za infuziju
novartis ba d.o.o. - gemcitabin - koncentrat za rastvor za infuziju - 10 mg/1 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)
gemcitabin ebewe 10 mg/1 ml koncentrat za rastvor za infuziju
novartis ba d.o.o. - gemcitabin - koncentrat za rastvor za infuziju - 10 mg/1 ml - 100 ml koncentrata za rastvor za infuziju sadrži: 1000 mg gemcitabina (u obliku gemcitabinhidrohlorida)
erlotinib actavis 25 mg/1 tableta film tableta
pliva d.o.o.sarajevo - erlotinib - film tableta - 25 mg/1 tableta - 1 film tableta sadrži: 25 mg erlotiniba (u obliku erlotinib hidrohlorida )